

Milestones 2021

The United Nations' 2030 Agenda for Sustainable Development was adopted as a shared blueprint for peace and prosperity for people and planet. The goals call for urgent action to end economic and social challenges such as poverty, hunger, discrimination against women and girls, while improving health, education and tackling climate change. MMV and partners recognize that the 17 Sustainable Development Goals are integrated, that action in one area will affect outcomes in others, and that equitable development must balance social and economic sustainability. With a focus on our malaria work, in 2021, we also aimed to contribute to the achievement of several additional SDGs.



Access to affordable and effective antimalarials is key to eliminating malaria, a major cause of poverty.

MMV has assembled the largest ever portfolio of antimalarials supporting target 3.3, which aims to end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases.

MMV prioritizes the needs of women and girls of reproductive age, a key population at risk of malaria.

Availability of antimalarials for workers and their families in affected areas decreases absenteeism in the workplace. It also decreases absenteeism at school which fosters future work opportunities.

MMV invests in partnerships, including those which strengthen research and manufacturing capacity in Africa.

MMV's vision is a world in which antimalarials cure and protect the most vulnerable and under-served populations.

Partnership is at the core of the PDP model, bringing together academia, pharma, research institutes, philanthropic organizations and funders.

1 3 10

450 million **Coartem® Dispersible** (artemether-lumefantrine) paediatric treatments distributed in over 50 countries since 2009, saving more than 960,000 children's lives

1 3 8 10

255 million vials of **injectable artesunate** delivered since 2010, saving an estimated 1.66 million additional lives compared to treatment with injectable quinine¹

1 3 8 10

7.6 million **artesunate rectal capsules** distributed since 2018, saving more than 780,000 lives

10

The **Severe Malaria Observatory**² is widely regarded as an instrumental resource for severe malaria information, recording an average of 34,000 sessions per month in 2021

1 3 8 10

8.6 million **Eurartesim®** (dihydroartemisinin-piperaquine) treatments distributed between 2011 and 2021

1 3 8 10

2.8 million **Pyramax®** (pyronaridine-artesunate) treatments delivered to date, with registration in 29 countries – of which about half were the paediatric granules formulation

¹ Assuming that patients would have received injectable quinine in the absence of injectable artesunate.
² Knowledge sharing for severe: <https://www.severemalaria.org/>

1 3 8 10

540 million **ASAQ Winthrop®** treatments delivered to date, with registration in 33 countries

1 3 8 10

728 million courses of **sulphadoxine-pyrimethamine and amodiaquine (SPAQ)** have been delivered since the launch of seasonal malaria chemoprevention (SMC) in 2014. In 2021 alone, over 44 million children in 13 countries were protected

1 3 8 10

Kozenis/Krintafel (tafenoquine)³ received regulatory approval in Peru for prevention of *P. vivax* relapse

1 3 8 10

TRuST feasibility study, representing first real-world application of tafenoquine, began in September 2021 with interim results received in December

1 3 8 10 17

The **Partnership for Vivax Elimination (PAVE)** was launched in 2021 with PATH, Menzies School of Health Research and the Burnet Institute to accelerate elimination of relapsing of *P. vivax* malaria

3 8 9 10

B&O Pharma selected as a manufacturing partner for **low-dose primaquine** for the prevention of relapse *P. vivax* malaria

3 5 9 10

One pregnancy registry established in Kenya, with permission granted for expansion to Burkina Faso

1 3 8 10

Ganaplacide-lumefantrine yielded positive results in a Phase IIb trial, supporting the continued development of the combination for uncomplicated malaria

3

ZY19489 + ferroquine yielded positive results in Phase I studies, demonstrating potent antimalarial activity

3

M5717 + pyronaridine selected as a new combination for development

3

GSK484 selected as MMV's Project of the Year 2021

3

IWY357 selected as a new candidate for development

3 8 9

Technology transfer resulted in the opening of a testing centre for resistance profiling in Burkina Faso

3 5 10

Studies have shown the **zebrafish assay** to be a reliable tool for the prediction of embryotoxicity in mammals, which could help pave the way for earlier inclusion of pregnant women in clinical trials

3 9 17

MMV has built an extensive **network of over 400 partners in 50 countries** since its inception in 1999

³ Trademarks are owned by or licensed to the GSK group of companies